Inhibition of Sphingolipid Metabolism in Osteosarcoma Protects Against CD151-mediated Tumorigenicity.

Wang Hongsheng,Jin Xinmeng,Zhang Yangfeng,Wang Zhuoying,Zhang Tao,Xu Jing,Shen Jiakang,Zan Pengfei,Sun Mengxiong,Wang Chongren,Hua Yingqi,Ma Xiaojun,Sun Wei

DOI: https://doi.org/10.1186/s13578-022-00900-9

2022-01-01

Cell & Bioscience

Abstract:Osteosarcoma is the most common primary bone tumor, with a poor prognosis owing to the lack of efficient molecular-based targeted therapies. Previous studies have suggested an association between CD151 and distinct consequences in osteosarcoma tumorigenicity. However, the potential of CD151 as a therapeutic target has not yet been sufficiently explored. Here, we performed integrated transcriptomic and metabolomic analyses of osteosarcoma and identified sphingolipid metabolism as the top CD151-regulated pathway. CD151 regulates sphingolipid metabolism primarily through SPTCL1, the first rate-limiting enzyme in sphingolipid biosynthesis. Mechanistically, depletion of CD151 enhanced c-myc polyubiquitination and subsequent degradation. c-myc is vital for the transcriptional activation of SPTLC1. Functionally, sphingolipid synthesis and the SPTLC1 inhibitor, myriocin, significantly suppressed the clonogenic growth of CD151-overexpression cells. Importantly, myriocin selectively restrained CD151-high expression tumor growth in preclinical patient-derived xenograft models. Collectively, these data establish that CD151 is a key mediator of sphingolipid metabolism and provide a new approach to developing novel CD151-based targeted therapies for osteosarcoma.